Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Gattii
97%
Cryptococcosis
84%
Colombia
77%
Molecular Subtypes
69%
Cryptococcus Gattii
68%
Neoformans
61%
Cryptococcus Neoformans
60%
Cryptococcus
54%
Antifungal Susceptibility
53%
Candida Albicans (C. albicans)
46%
Antimicrobial Peptides
39%
Core Genome multilocus Sequence Typing (cgMLST)
38%
Genetic Diversity
33%
Fluconazole
30%
Aurès
28%
Candida Species
27%
Mycoses
26%
Candida Auris
26%
Epidemiology
25%
Virulence
24%
Biofilm
24%
Cryptococcus Gattii Species Complex
23%
Genotype
23%
Latin America (LATAM)
22%
Molecular Epidemiology
22%
C. Parapsilosis
20%
Candida Parapsilosis
20%
C.albicans
19%
Voriconazole
19%
Sequence Type
19%
Mating Type
16%
Antifungal Activity
15%
Veterinary
15%
Fluconazole Resistance
15%
Colombian
15%
Antifungal Resistance
15%
Genotypic Diversity
14%
Biofilm Formation
14%
Murine Model
14%
Amphotericin B
13%
North America
13%
Fungal Infection
13%
Azole Resistance
13%
Cryptococcal Meningitis
12%
Azoles
12%
Virulent Strain
12%
Pore-forming Peptide
12%
Aspergillus Fumigatus
11%
Invasive Candidiasis
11%
Peru
11%
Immunology and Microbiology
Infectious Disease
100%
Infection
100%
Cryptococcus gattii
76%
Cryptococcus neoformans
73%
Multilocus Sequence Typing
57%
Antifungal Susceptibility
50%
Peptides
46%
Genetic Variability
43%
Candida albicans
42%
Biofilm
38%
Filobasidiella
38%
Human immunodeficiency virus
36%
Candida
36%
Serotype
34%
Antimicrobial Peptides
31%
Infectious Agent
29%
Cohort Effect
27%
Epidemiology
22%
Meningitis
22%
Minimum Inhibitory Concentration
21%
Susceptibility
21%
Antifungal Activity
20%
Candida parapsilosis
20%
Molecular Epidemiology
17%
Candida Auris
16%
Cladistics
16%
In Vitro
15%
Aspergillosis
14%
Antifungal Resistance
14%
Antigen
13%
Aspergillus fumigatus
11%
Galleria mellonella
11%
Prevalence
11%
Candidozyma auris
10%
Wild Type
10%
Whole Genome Sequencing
10%
Central Nervous System
9%
Microorganism
9%
Matrix-Assisted Laser Desorption-Ionization
9%
Time-of-Flight Mass Spectrometry
9%
Systemic Lupus Erythematosus
9%
Systemic Scleroderma
9%
Streptococcus pneumonia
9%
Antimicrobial Agent
8%
Mortality Rate
7%
MIC50
7%
Immune System
7%
Immunocompromised Patient
7%
Pathogenic Potential
7%
Virulence Factor
6%